S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:CODX - Co-Diagnostics Stock Price, Forecast & News

$4.32
+0.39 (+9.94 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$3.62
Now: $4.32
$4.60
50-Day Range
$0.92
MA: $2.34
$3.96
52-Week Range
$0.69
Now: $4.32
$4.60
Volume14.20 million shs
Average Volume7.81 million shs
Market Capitalization$93.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value($0.08) per share

Profitability

Net Income$-6,270,000.00
Net Margins-5,486.08%

Miscellaneous

Employees22
Market Cap$93.17 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.


Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics Inc (NASDAQ:CODX) issued its earnings results on Wednesday, November, 13th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million. Co-Diagnostics had a negative return on equity of 202.74% and a negative net margin of 5,486.08%. View Co-Diagnostics' Earnings History.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Co-Diagnostics.

What price target have analysts set for CODX?

2 analysts have issued 1 year price targets for Co-Diagnostics' stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Co-Diagnostics' stock price to reach $3.00 in the next year. This suggests that the stock has a possible downside of 30.5%. View Analyst Price Targets for Co-Diagnostics.

What is the consensus analysts' recommendation for Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Co-Diagnostics.

Has Co-Diagnostics been receiving favorable news coverage?

News stories about CODX stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Co-Diagnostics earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Co-Diagnostics.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA), Ibio (IBIO), FuelCell Energy (FCEL), Inpixon (INPX), Actinium Pharmaceuticals (ATNM), Tonix Pharmaceuticals (TNXP), vTv Therapeutics (VTVT) and Kopin (KOPN).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the folowing people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 66)
  • Dr. Brent C. Satterfield, Co-Founder, Chief Science Officer & Director (Age 42)
  • Mr. Reed L. Benson, CFO, Gen. Counsel & Sec. (Age 71)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Barclays PLC (0.50%) and Virtu Financial LLC (0.22%). View Institutional Ownership Trends for Co-Diagnostics.

Which institutional investors are buying Co-Diagnostics stock?

CODX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Barclays PLC. View Insider Buying and Selling for Co-Diagnostics.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $4.32.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $93.17 million and generates $40,000.00 in revenue each year. Co-Diagnostics employs 22 workers across the globe.View Additional Information About Co-Diagnostics.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is http://www.codiagnostics.com/.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE - D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]


MarketBeat Community Rating for Co-Diagnostics (NASDAQ CODX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  222 (Thanks for Voting!)
Underperform Votes:  248 (Thanks for Voting!)
Total Votes:  470
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Float

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel